Latest News

You can find our latest news below

19 Jun, 2024

We will be attending the 2024 ADLM Clinical Lab Expo from July 28 to August 1.

18 Jun, 2024

By choosing to buy locally, you not only support the North American branch but also ensure a smoother, more cost-effective purchasing experience.

10 Jun, 2024

We are excited to announce the launch of a new recombinant Anti-CA-125 antibody RX16 (Cat# 4C29).

29 May, 2024

May is Cancer Survivor Month. We honor the strength, resilience, and courage of cancer survivors around the world.

15 May, 2024

We are excited to announce the launch of a new recombinant Glial Fibrillary Acidic Protein (GFAP) antigen, Cat# 8G47.

11 Apr, 2024

Hytest is pleased to announce the addition of recombinant monoclonal antibodies RC3A6 and RC8E2 (Cat. # 2I1) to our Insulin product portfolio.

28 Mar, 2024

Our monoclonal antibodies (MAbs) can recognize up to 16 different strains of the influenza A virus. 

01 Mar, 2024

Meet HyTest team at the China Association of Clinical Laboratory Practice Expo!

01 Mar, 2024

Launch of HyTest’s latest monoclonal antibodies targeting the nucleoprotein of influenza B virus!

01 Mar, 2024

The Brain Injury Association of America (BIAA) designates March as a month to raise awareness about brain injuries.

01 Mar, 2024

We are pleased to inform you that Hytest North America, a subsidiary of Hytest Ltd, will launch local operations in March 2024!

31 Jan, 2024

February is American Heart Month, emphasizing the importance of heart health, with a focus on women this year due to their unique risk and often underdiagnosed heart conditions. Current AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain highlight the gender-specific nature of heart disease diagnosis, particularly noting that women generally have lower baseline levels of troponin.

At HyTest, we are dedicated to meeting this gender-specific diagnostic need through our innovations in cardiac diagnostics, especially in troponins. Our product range includes approximately 50 antibodies targeting various epitopes of the cardiac troponin I (cTnI) molecule, complemented by our advanced cardiac troponin and troponin complex antigens. For more detailed information, please refer to our Cardiac Markers Brochure.

04 Jan, 2024

HyTest antibodies should recognize Pirola and Eris variants.

19 Dec, 2023

Procollagen type I N-propetide (PINP) in blood is recommended as a reference marker for bone formation in osteoporosis by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry (IFCC) bone marker standards joint working group. PINP, in particular, has emerged as a recommended reference marker for bone formation in osteoporosis, aiding in monitoring antiresorptive and anabolic therapies.

30 Nov, 2023

This distinguished award seeks to recognize and honours outstanding individuals who have made significant contributions to the field of Cardiovascular Diagnostics.

30 Nov, 2023

At HyTest, our specialization in cardiac troponin (cTn) detection spans nearly three decades. Over the years, we have generated and analysed thousands of cTn-specific antibodies.

31 Oct, 2023

We're delighted to announce the launch of our latest troponin product: the recombinant chimeric human Cardiac Troponin binary Complex (Cat. # 8IFC20). This unique complex features the most stable part of cTnI (fragment 28-110) linked with TnC by a 20-aar flexible linker of the cTn I – C complex.

27 Sep, 2023

We will be attending Medica 2023 in November.

05 Jul, 2023

We have been privileged to have Soozy and Linda on our team for about 10 years. Now the story continues with new job descriptions – Soozy Xi will continue as CCO of HyTest and Linda Li will take on the role of General Manager of HyTest China. The whole team warmly congratulates! We also got a few comments from them:

05 Jul, 2023

Procalcitonin (PCT) is an established biomarker, which is used to guide antibiotic treatment in septic patient. As an invaluable indicator, it shows high sensitivity and specificity for bacterial infection. Given the utility of PCT in clinical setting, variability in results from different commercial assays have been observed. In this webinar, participants will have the opportunity to review the clinical application of PCT, technology used for PCT measurements and also the challenges in terms of the standardization effort.

Do you need samples?

We are happy to make you an offer